Oral Minoxidil Side Effects: Incidence Rates Across Clinical Trials

Where the incidence numbers come from

No oral minoxidil product is FDA-approved for hair loss [3]. The tablets are approved only for hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum doses of a diuretic plus two other antihypertensive drugs, and the label states that use of minoxidil tablets, in any formulation, to promote hair growth is not an approved indication [3]. The low-dose hair-loss figures below therefore come from off-label use. The tablet label also reports adverse-effect rates from hypertension treatment [3].

The largest safety dataset is a retrospective multicenter study of 1,404 patients (943 women, 461 men; mean age 43) treated with low-dose oral minoxidil for at least 3 months, with no control group [1]. The pooled blood pressure and heart rate figures come from a systematic review and meta-analysis of uncontrolled studies using 5 mg/day or less [2].

Hypertrichosis: the most common side effect

Unwanted hair growth away from the scalp was the most frequent adverse effect in the 1,404-patient series, at 15.1%, and it led to withdrawal in 14 patients [1]. In the pooled low-dose analysis it was also the most frequent side effect and accounted for 34.6% of discontinuations [2].

Dose matters. A meta-regression of six studies in androgenetic alopecia found that each additional 1 mg/day of low-dose oral minoxidil was associated, at 6 months, with a mean difference of 17.9% in hypertrichosis risk and 4.8% in cardiovascular adverse-event risk. These are observational associations, and the authors say randomized trials are needed to show causation [6].

At antihypertensive doses the label reports hypertrichosis in about 80% of patients taking minoxidil tablets, developing within 3 to 6 weeks. It is usually first noticed at the temples, between the eyebrows, between the hairline and the eyebrows, or in the sideburn area, and later extends to the back, arms, legs and scalp [3]. The label states that no endocrine abnormalities have been found to explain the hair growth, and that 1 to 6 months may be needed for a return to pretreatment appearance after the drug is stopped [3].

Fluid retention and edema

Fluid retention was reported in 1.3% and periorbital edema in 0.3% of the 1,404-patient series [1]. The label's figures come from a different population and dose range. It reports reversible edema in approximately 10% of non-dialysis patients who were treated with an adequate diuretic [3], and temporary edema in 7% of patients who were not edematous at the start of therapy [3]. The label requires a diuretic, frequently a loop diuretic, to prevent serious fluid accumulation, and notes that without one, retention of several hundred milliequivalents of salt and corresponding water can occur within a few days [3]. The label also says body weight should be monitored closely [3].

Heart rate, blood pressure and lightheadedness

The 2025 meta-analysis found no significant change in systolic blood pressure (mean difference -0.13 mm Hg, 95% CI -2.67 to 2.41) or diastolic blood pressure (-1.25 mm Hg, 95% CI -3.21 to 0.71), but a significant mean increase in heart rate of 2.67 beats per minute (95% CI 0.34 to 5.01) [2]. Hypotensive symptoms were reported in 119 patients (5.0%), and no hypotensive episodes occurred [2]. In the 1,404-patient series, tachycardia was recorded in 0.9% and lightheadedness in 1.7% [1].

The label describes these events as predictable consequences of vasodilation: the fall in peripheral resistance triggers reflex increases in heart rate, cardiac output, renin and salt and water retention, which is why a beta blocker and a diuretic are usually required at antihypertensive doses [3]. The boxed warning states that angina pectoris may be exacerbated [3].

Pericardial effusion and serious cardiac events

The boxed warning covers pericardial effusion, occasionally progressing to tamponade, along with fluid retention and worsening angina, and reserves the drug for hypertensive patients who do not respond to maximum doses of a diuretic and two other antihypertensives [3]. The label reports effusion in about 3% of treated patients not on dialysis, especially those with inadequate or compromised renal function, and says patients should be observed closely for any suggestion of a pericardial disorder, with echocardiography if suspicion arises [3].

Those figures describe hypertension dosing. In the 1,404-patient low-dose series, the authors reported no life-threatening adverse effects [1]. That study was retrospective and had no control group, so it cannot establish how often a rare event occurs at low doses [1].

Other reported effects

Headache was reported in 0.4% and insomnia in 0.2% of the 1,404 patients [1]. At antihypertensive doses the label lists ECG T-wave changes in approximately 60% of patients, which usually disappear with continued treatment and have no symptoms attached [3]; a fall of about 7% in hematocrit, hemoglobin and red cell count that later recovers [3]; breast tenderness in less than 1% [3]; rare thrombocytopenia and leukopenia [3]; and rare rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis [3]. Serum creatinine increased an average of 6% and BUN slightly more, then declined toward pretreatment levels [3].

Do FDA adverse event reports give incidence rates?

They do not. The FDA's adverse event dashboard states that the information in reports cannot be used to estimate the incidence of the events reported, that duplicate and incomplete reports exist, and that a report does not establish that the drug caused the event [7]. The rates on this page come from cohort and trial data rather than report counts.